IgA-alpha-1-antitrypsin complex in systemic lupus erythematosus: preliminary report

Area of Science:

• Immunology
• Rheumatology
• Clinical Chemistry

Background:

• Systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD) are autoimmune disorders with complex pathogenesis.
• The IgA-alpha-1-antitrypsin (IgA-AT) complex is a potential biomarker, but its role in SLE and MCTD requires further investigation.

Purpose of the Study:

• To investigate the role of the IgA-AT complex in SLE and MCTD.
• To assess the relationship between IgA-AT levels and disease activity or treatment in these conditions.

Main Methods:

• Serum samples from 65 SLE patients and 9 MCTD patients were analyzed.
• IgA-AT complex concentrations were measured using a double antibody enzyme-linked immunoassay (ELISA).
• Comparisons were made with healthy controls and correlations with clinical parameters were assessed.

Main Results:

• Elevated IgA-AT complex levels were observed in 44.6% of SLE patients and 33.3% of MCTD patients compared to controls.
• SLE patients with neurological manifestations showed significantly higher IgA-AT levels (P < 0.001).
• Patients treated with cyclophosphamide (CTX) exhibited increased IgA-AT levels compared to untreated SLE patients (P < 0.05).

Conclusions:

• IgA-AT complex is increased in SLE and MCTD patients, suggesting its involvement in these autoimmune diseases.
• Elevated IgA-AT levels are particularly associated with central nervous system (CNS) involvement in SLE.
• The IgA-AT complex may serve as a potential biomarker for disease activity and treatment response in SLE and MCTD.